537 related articles for article (PubMed ID: 26192916)
21. Analysis of clonality in cutaneous T cell lymphoma and associated diseases.
Wood GS
Ann N Y Acad Sci; 2001 Sep; 941():26-30. PubMed ID: 11594579
[TBL] [Abstract][Full Text] [Related]
22. MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53.
Manfé V; Biskup E; Johansen P; Kamstrup MR; Krejsgaard TF; Morling N; Wulf HC; Gniadecki R
J Invest Dermatol; 2012 May; 132(5):1487-96. PubMed ID: 22377766
[TBL] [Abstract][Full Text] [Related]
23. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
24. Telomerase activity and telomere length in lymphocytes from patients with cutaneous T-cell lymphoma.
Wu K; Lund M; Bang K; Thestrup-Pedersen K
Cancer; 1999 Sep; 86(6):1056-63. PubMed ID: 10491534
[TBL] [Abstract][Full Text] [Related]
25. Role of high-throughput sequencing in the diagnosis of cutaneous T-cell lymphoma.
Rea B; Haun P; Emerson R; Vignali M; Farooqi M; Samimi S; Elenitsas R; Kirsch I; Bagg A
J Clin Pathol; 2018 Sep; 71(9):814-820. PubMed ID: 29636372
[TBL] [Abstract][Full Text] [Related]
26. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
[TBL] [Abstract][Full Text] [Related]
27. Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma.
Iyer A; Hennessey D; O'Keefe S; Patterson J; Wang W; Wong GK; Gniadecki R
Blood Adv; 2020 Jun; 4(11):2489-2500. PubMed ID: 32502269
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
Kitadate A; Ikeda S; Teshima K; Ito M; Toyota I; Hasunuma N; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncogene; 2016 Jul; 35(28):3692-704. PubMed ID: 26640145
[TBL] [Abstract][Full Text] [Related]
29. Cutaneous T-cell lymphoma: molecular and cytogenetic findings.
Sterry W
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):13-7. PubMed ID: 17474354
[TBL] [Abstract][Full Text] [Related]
30. Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL).
Wu J; Siddiqui J; Nihal M; Vonderheid EC; Wood GS
Arch Biochem Biophys; 2011 Apr; 508(2):185-91. PubMed ID: 21036138
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous manifestations of Epstein-Barr virus-associated T-cell lymphoma.
Su IJ; Tsai TF; Cheng AL; Chen CC
J Am Acad Dermatol; 1993 Nov; 29(5 Pt 1):685-92. PubMed ID: 8227539
[TBL] [Abstract][Full Text] [Related]
32. Advances in the understanding and treatment of Cutaneous T-cell Lymphoma.
Bakr FS; Whittaker SJ
Front Oncol; 2022; 12():1043254. PubMed ID: 36505788
[TBL] [Abstract][Full Text] [Related]
33. Non-coding RNAs in the epigenetic landscape of cutaneous T-cell lymphoma.
Adeeb M; Therachiyil L; Moton S; Buddenkotte J; Alam MA; Uddin S; Steinhoff M; Ahmad A
Int Rev Cell Mol Biol; 2023; 380():149-171. PubMed ID: 37657857
[TBL] [Abstract][Full Text] [Related]
34. Chromosomal imbalances: a hallmark of tumour relapse in primary cutaneous CD30+ T-cell lymphoma.
Prochazkova M; Chevret E; Beylot-Barry M; Sobotka J; Vergier B; Delaunay M; Turmo M; Ferrer J; Kuglik P; Merlio JP
J Pathol; 2003 Nov; 201(3):421-9. PubMed ID: 14595754
[TBL] [Abstract][Full Text] [Related]
35. Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma.
Andrews JM; Schmidt JA; Carson KR; Musiek AC; Mehta-Shah N; Payton JE
EBioMedicine; 2019 Aug; 46():170-183. PubMed ID: 31358475
[TBL] [Abstract][Full Text] [Related]
36. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Kamata M; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Clin Cancer Res; 2011 Dec; 17(24):7529-38. PubMed ID: 22048239
[TBL] [Abstract][Full Text] [Related]
37. Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis.
Abdulrahman N; Leo R; Boumenar HA; Ahmad F; Mateo JM; Jochebeth A; Al-Sowaidi NK; Sher G; Ansari AW; Alam M; Uddin S; Ahmad A; Steinhoff M; Buddenkotte J
Leuk Lymphoma; 2023 Dec; 64(14):2236-2248. PubMed ID: 37708450
[TBL] [Abstract][Full Text] [Related]
38. Lack of expression of the recombination activating genes RAG-1 and RAG-2 in cutaneous T-cell lymphoma: pathogenic implications.
Döbbeling U; Dummer R; Hess Schmid M; Burg G
Clin Exp Dermatol; 1997 Sep; 22(5):230-3. PubMed ID: 9536544
[TBL] [Abstract][Full Text] [Related]
39. Molecular techniques drive cutting edge advancements in management of cutaneous T cell lymphoma.
Lefebvre MN; Borcherding N; Reis RJ; Mou E; Liu V; Jabbari A
Front Immunol; 2023; 14():1228563. PubMed ID: 37654486
[TBL] [Abstract][Full Text] [Related]
40. Single-cell transcriptomics links malignant T cells to the tumor immune landscape in cutaneous T cell lymphoma.
Liu X; Jin S; Hu S; Li R; Pan H; Liu Y; Lai P; Xu D; Sun J; Liu Z; Gao Y; Zhao Y; Liu F; Xiao Y; Li Y; Wen Y; Chen Z; Xu B; Lin Y; Ran M; Li Q; Yang S; Li H; Tu P; Haniffa M; Teichmann SA; Bai F; Wang Y
Nat Commun; 2022 Mar; 13(1):1158. PubMed ID: 35241665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
